Machine learning enhances radiology workflows by improving diagnostic accuracy and enabling faster results. Imaging demand, radiologist shortages, and regulatory approvals drive global adoption. Cloud-based and tele-radiology solutions support remote diagnostics. Oncology leads applications, while CT and MRI dominate modalities. North America leads, Asia Pacific grows due to expanding healthcare infrastructure.
According to a research study published by Knowledge Sourcing Intelligence (KSI), the machine learning–based diagnostic imaging platforms market will expand from USD 2.1 billion in 2026 to USD 5.1 billion in 2031 at a CAGR of 19.4% during the forecast period.
The market is expected to experience strong growth because medical imaging facilities are adopting artificial intelligence technology for medical diagnosis purposes.
Access sample report or view details: https://www.knowledge-sourcing.com/report/machine-learningbased-diagnostic-imaging-platforms-market/request
Key Market Insight & Emerging Trends:
The diagnostic accuracy of radiology workflows improves through the implementation of machine learning algorithms because it enables faster diagnosis results. AI platforms help healthcare organizations manage their increasing imaging demands, which result from their need to overcome the shortage of available radiologists. The worldwide adoption of AI imaging tools has accelerated because healthcare organizations received regulatory approval for these technologies, while digital health infrastructure investments increased.
Additionally, tele-radiology services and cloud-based imaging systems enable healthcare organizations to conduct remote diagnostics while their professionals share information in real time. The rising number of patients with chronic conditions like cancer, cardiovascular disorders, and neurological diseases is increasing the need for better imaging technology.
The Asia Pacific region shows strong growth potential because its healthcare facilities expand, its government programs support AI technology adoption, and its large patient base.
North America maintained market leadership in 2026 through its substantial market share.
The software segment will experience the fastest growth during the upcoming years because deep learning model technology continues to make progress.
CT and MRI imaging methods will become the dominant modalities for complex disease assessments because of their widespread usage.
The oncology application segment will become the largest market segment because of rising cancer rates and the demand for early cancer detection.
Market leaders are pursuing AI research and development while forming strategic partnerships and obtaining regulatory approvals to increase their market presence. Meanwhile, emerging startups are also playing a crucial role by developing niche AI solutions for specific imaging applications.
Component Insights: Software Segment at the Forefront
The software segment held the greatest market share during 2026 because it provided essential functionalities needed for image analysis and pattern recognition, and clinical decision support. AI-powered software enables automation of workflows, which leads to better diagnostic results while decreasing the possibility of human mistakes. Increasing usage of cloud-based AI platforms creates additional opportunities for the segment to expand.
Modality Insights: CT Imaging as a Core Revenue Contributor
Computed Tomography (CT) modality dominates the market because it serves as the primary method for identifying complex medical conditions, which include tumors and cardiovascular abnormalities. The introduction of machine learning to CT systems allows for quicker image analysis and more accurate results through advanced diagnostic capabilities.
Application Insights: Oncology Driving Maximum Adoption
Oncology remains the leading application segment as Machine Learning technology is used for early tumor detection and treatment planning, and monitoring activities drive oncological research advancement. The segment grows because patients need precise treatment solutions, which is driven by rising global cancer rates.
Regional Highlights: North America Leading, Asia Pacific Accelerating
North America controls a substantial market share as the region possesses superior healthcare facilities and advanced AI systems, and major technology companies establish their operations there. The market expansion in the region receives support from research and development funding, together with business-friendly regulatory environments. The Asia Pacific region will experience rapid growth throughout the forecasted period because of its rising digital health projects and growing healthcare technology accessibility.
Competitive Landscape
As a part of the report, the major players operating in the machine learning–based diagnostic imaging platforms market have been covered, such as Siemens Healthineers, GE HealthCare, Philips Healthcare, Canon Medical Systems, Fujifilm Healthcare, IBM Watson Health, Aidoc, Zebra Medical Vision, Tempus, and Butterfly Network. These companies are actively engaged in product launches, partnerships, and technological advancements to expand their AI imaging portfolios and strengthen their global presence.
Market Segmentation
The report segments the Machine Learning–Based Diagnostic Imaging Platforms Market as follows:
By Component
o Software
o Hardware
o Services
By Imaging Modality
o X-ray
o Computed Tomography (CT)
o Magnetic Resonance Imaging (MRI)
o Ultrasound
o Positron Emission Tomography (PET)
o Mammography
By Application
o Oncology
o Cardiology
o Neurology
o Orthopedics
o Pulmonology
By Geography
North America
USA
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Others
Asia Pacific
China
India
Japan
South Korea
Indonesia
Thailand
Others
Companies Profiled:
Siemens Healthineers
GE HealthCare
Philips Healthcare
Canon Medical Systems
Fujifilm Healthcare
IBM Watson Health
Aidoc
Zebra Medical Vision
Tempus
Butterfly Network
Explore More Reports:
Need specialized data cuts or competitive intelligence?
Our analyst team provides bespoke market sizing, supplier audits, and country-level feasibility reports tailored to your enterprise roadmap.
Speak With an Industry Analyst →Ask an Industry Analyst
Have questions regarding this briefing or market projections? Inquire with our sector lead.
Related Press Releases
View All →
ADC Manufacturing & CDMO Market is expected to reach USD 10.49 billion by 2031
Aug 7, 2026
Lifestyle-Associated Cancer Epidemiology Market is expected to reach USD 13.12 billion by 2031
Aug 5, 2026
Psycho-Oncology Digital Health Market is anticipated to surpass USD 290.01 million in 2031 at a CAGR of 8.5%
Jul 30, 2026
Intratumoral Injection Therapy Market is expected to reach USD 630.39 million by 2031
Jul 24, 2026
Palliative Care in Oncology Market is expected to reach USD 244.1 billion by 2031
Jul 22, 2026More Press Releases
Oncology Drug Resistance Testing Market is projected to reach USD 3.41 billion in 2031 at a CAGR of 6.6 %
The oncology drug resistance testing market is expanding due to rising cancer prevalence, increasing drug resistance, and growing adoption of precision oncology. Advances in NGS-based testing, companion diagnostics, and targeted therapies, alongside FDA approvals and investments in personalized medicine, are accelerating demand for effective resistance monitoring across hospitals and clinical diagnostics worldwide.
TROP-2 Targeted Therapy Market is anticipated to surpass USD 3.29 billion in 2031 at a CAGR of 8.6 %
The TROP-2 Targeted Therapy market is expanding rapidly due to increasing precision oncology adoption, rising cancer prevalence, and growing use of antibody-drug conjugates. North America leads the market, while Asia Pacific shows the fastest growth. Continuous clinical trials, regulatory approvals, and strategic collaborations are accelerating innovation and commercial adoption worldwide.
Second Primary Cancer Prevention Market is expected to reach USD 24.7 billion by 2031
The Second primary cancer prevention refers to strategies aimed at reducing the risk of developing a new, unrelated cancer in individuals with a prior cancer diagnosis. Growing cancer survivorship, advances in treatment, and increasing awareness of long-term health outcomes have heightened the importance of prevention and surveillance programs. Key approaches include routine screening, genetic risk assessment, lifestyle modification, and long-term follow-up care. Government agencies and healthcare organisations increasingly emphasise survivorship care plans and evidence-based screening protocols to detect new malignancies at earlier stages. Continued investments in early detection technologies and personalised risk assessment are expected to support advancements in second primary cancer prevention.